. Author manuscript; available in PMC: 2013 Jun 24.

Published in final edited form as: Gastroenterology. 2009 May 7;136(6):1939–1951. doi: 10.1053/j.gastro.2009.02.076

Table 1.

Comparison of the Two Licensed Rotavirus Vaccines ^**

	Rotateq^™	Rotarix^™
Manufacturer	Merck Vaccine Division	GlaxoSmithKline
Genetic Backbone	Bovine Rotavirus-WC3	Human rotavirus-89-12
Composition	5 human; bovine reassortant	Single human rotavirus
Genotypes	G1,2,3,4 and [P8]	G1 [P8]
Dosage schedule	3 doses @ 2, 4, & 6 months of age	2 doses @ 2 & 4 months of age
Administration	Oral	Oral
Presentation	Liquid	Lyophilized-reconstituted
^* Protection against severe disease	85% (72–92)	95% (91–97)^*
Virus shedding	9%	50% or more
Intussusception	No	No

different scoring systems used so results not directly comparable

^**

adapted From Dennehy 2008,⁷⁸ and Grimwood 2008 ⁸¹